Acridine Carboxamide
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Acridine Carboxamide
- DrugBank Accession Number
- DB11880
- Background
Acridine Carboxamide has been used in trials studying the treatment of Lung Cancer and Brain and Central Nervous System Tumors.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 293.37
Monoisotopic: 293.152812244 - Chemical Formula
- C18H19N3O
- Synonyms
- 4-ACRIDINECARBOXAMIDE, N-(2-(DIMETHYLAMINO)ETHYL)-
- DACA
- N-(2-(DIMETHYLAMINO)ETHYL)ACRIDINE-4-CARBOXAMIDE
- External IDs
- NSC 601316
- NSC-601316
- XR-5000
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAmbroxol The risk or severity of methemoglobinemia can be increased when Acridine Carboxamide is combined with Ambroxol. Articaine The risk or severity of methemoglobinemia can be increased when Acridine Carboxamide is combined with Articaine. Benzocaine The risk or severity of methemoglobinemia can be increased when Acridine Carboxamide is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Acridine Carboxamide is combined with Benzyl alcohol. Bupivacaine The risk or severity of methemoglobinemia can be increased when Acridine Carboxamide is combined with Bupivacaine. - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as acridines. These are organic compounds containing the acridine moiety, a linear tricyclic heterocycle which consists of two benzene rings joined by a pyridine ring.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Quinolines and derivatives
- Sub Class
- Benzoquinolines
- Direct Parent
- Acridines
- Alternative Parents
- Quinoline carboxamides / Pyridines and derivatives / Benzenoids / Heteroaromatic compounds / Trialkylamines / Secondary carboxylic acid amides / Amino acids and derivatives / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds show 2 more
- Substituents
- Acridine / Amine / Amino acid or derivatives / Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Carboxamide group / Carboxylic acid derivative / Heteroaromatic compound / Hydrocarbon derivative show 11 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 0N3V8R4E13
- CAS number
- 89459-25-6
- InChI Key
- XBGNERSKEKDZDS-UHFFFAOYSA-N
- InChI
- InChI=1S/C18H19N3O/c1-21(2)11-10-19-18(22)15-8-5-7-14-12-13-6-3-4-9-16(13)20-17(14)15/h3-9,12H,10-11H2,1-2H3,(H,19,22)
- IUPAC Name
- N-[2-(dimethylamino)ethyl]acridine-4-carboxamide
- SMILES
- CN(C)CCNC(=O)C1=C2N=C3C=CC=CC3=CC2=CC=C1
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0250820
- PubChem Compound
- 107805
- PubChem Substance
- 347828217
- ChemSpider
- 96954
- ChEMBL
- CHEMBL9940
- ZINC
- ZINC000003787606
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data2 Completed Treatment Brain and Central Nervous System Tumors 1 somestatus stop reason just information to hide 2 Completed Treatment Lung Cancer 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0376 mg/mL ALOGPS logP 2.75 ALOGPS logP 2.6 Chemaxon logS -3.9 ALOGPS pKa (Strongest Acidic) 14.76 Chemaxon pKa (Strongest Basic) 8.51 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 45.23 Å2 Chemaxon Rotatable Bond Count 4 Chemaxon Refractivity 88.05 m3·mol-1 Chemaxon Polarizability 33.51 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-0a4i-8190000000-8a75c80ed9444565a3d3 Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-0006-0090000000-a811bbf379a26056219c Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-007c-7090000000-d38838fa8a01e328b425 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0a4i-2090000000-dd889c5c402a61682ba2 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-000i-9050000000-93e56ff89db715b4087a Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0ab9-7390000000-7abfdf9de22847df076e Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-004l-9840000000-4ab57da431ebbe310517 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 168.97176 predictedDeepCCS 1.0 (2019) [M+H]+ 171.32976 predictedDeepCCS 1.0 (2019) [M+Na]+ 177.42293 predictedDeepCCS 1.0 (2019)
Drug created at October 20, 2016 20:57 / Updated at July 31, 2024 09:44